Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc.
Kailera Therapeutics Inc is a clinical-stage biotechnology company developing a diversified pipeline of GLP-1 based therapeutics for obesity treatment. The company is advancing four clinical-stage candidates with multiple mechanisms of action and administration routes, targeting unmet needs in weight management.
When is the Kailera Therapeutics, Inc. IPO expected?
Kailera Therapeutics, Inc. has already gone public. It listed on April 17, 2026.
What is Kailera Therapeutics, Inc.'s valuation?
Kailera Therapeutics, Inc.'s estimated valuation is approximately $625M. The final valuation will depend on IPO pricing and market demand.
Can retail investors participate in the Kailera Therapeutics, Inc. IPO?
U.S. IPOs are typically allocated to institutional investors first. Retail investors can purchase shares on NASDAQ Global Select after listing. Some brokerages offer IPO access programs for pre-IPO allocation.
What does Kailera Therapeutics, Inc. do?
Kailera Therapeutics Inc is a clinical-stage biotechnology company developing a diversified pipeline of GLP-1 based therapeutics for obesity treatment. The company is advancing four clinical-stage candidates with multiple mechanisms of action and administration routes, targeting unmet needs in weight management.